New hope for Hard-to-Treat breast cancer: Dato-DXd trial opens
NCT ID NCT07205822
First seen Jun 25, 2026 · Last updated Jul 28, 2026 · Updated 4 times
Summary
This study is testing a drug called Dato-DXd in 100 people with a type of advanced breast cancer (HR-positive, HER2 IHC 0) that has stopped responding to hormone therapy. Participants receive the drug by IV every 3 weeks. The goal is to see if it can slow cancer growth and to check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dato-DXd (a drug given by IV every 3 weeks)
- What this could lead to
- If it works, this could offer a new treatment option for people with a common type of advanced breast cancer that has stopped responding to hormone therapy.
- What could go wrong
- This is an early Phase 3 study with only 100 participants, so results may not apply to everyone. Side effects like mouth sores and eye problems are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
WITHDRAWNLargo, Florida, 33770, United States
-
Research Site
RECRUITINGFort Wayne, Indiana, 46825, United States
-
Research Site
RECRUITINGOmaha, Nebraska, 68130, United States
-
Research Site
RECRUITINGNew York, New York, 10021, United States
-
Research Site
RECRUITINGHouston, Texas, 77024, United States
-
Research Site
RECRUITINGPuyallup, Washington, 98373, United States
-
Research Site
RECRUITINGBeijing, 100021, China
-
Research Site
RECRUITINGChangsha, 410013, China
-
Research Site
RECRUITINGGuangzhou, 510060, China
-
Research Site
RECRUITINGLinyi, 276001, China
-
Research Site
RECRUITINGShandong, 250117, China
-
Research Site
RECRUITINGWuhan, 430071, China
-
Research Site
NOT_YET_RECRUITINGZhengzhou, 450008, China
-
Research Site
RECRUITINGClermont-Ferrand, 63050, France
-
Research Site
RECRUITINGLa Roche-sur-Yon, 85925, France
-
Research Site
RECRUITINGMontpellier, 34070, France
-
Research Site
RECRUITINGParis, 75005, France
-
Research Site
RECRUITINGPierre-Bénite, 69310, France
-
Research Site
RECRUITINGAviano, 33081, Italy
-
Research Site
RECRUITINGFlorence, 50134, Italy
-
Research Site
RECRUITINGMeldola, 47014, Italy
-
Research Site
RECRUITINGMilan, 20141, Italy
-
Research Site
RECRUITINGNaples, 80131, Italy
-
Research Site
RECRUITINGRoma, 00168, Italy
-
Research Site
RECRUITINGBukgu, 41404, South Korea
-
Research Site
RECRUITINGGoyang-si, 410-769, South Korea
-
Research Site
RECRUITINGSeoul, 03080, South Korea
-
Research Site
RECRUITINGSeoul, 06273, South Korea
-
Research Site
RECRUITINGSeoul, 06351, South Korea
-
Research Site
RECRUITINGSeoul, 06591, South Korea
-
Research Site
RECRUITINGSeoul, 136705, South Korea
-
Research Site
RECRUITINGSeoul, 3722, South Korea
-
Research Site
RECRUITINGSeoul, 5505, South Korea
-
Research Site
RECRUITINGA Coruña, 15006, Spain
-
Research Site
RECRUITINGBarcelona, 08035, Spain
-
Research Site
RECRUITINGGranada, 18007, Spain
-
Research Site
RECRUITINGMadrid, 28033, Spain
-
Research Site
RECRUITINGMadrid, 28040, Spain
-
Research Site
RECRUITINGSeville, 41009, Spain
-
Research Site
RECRUITINGValencia, 46009, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?